CN102150838A - Weight losing composition, preparation containing same and preparation method thereof - Google Patents
Weight losing composition, preparation containing same and preparation method thereof Download PDFInfo
- Publication number
- CN102150838A CN102150838A CN2010106080995A CN201010608099A CN102150838A CN 102150838 A CN102150838 A CN 102150838A CN 2010106080995 A CN2010106080995 A CN 2010106080995A CN 201010608099 A CN201010608099 A CN 201010608099A CN 102150838 A CN102150838 A CN 102150838A
- Authority
- CN
- China
- Prior art keywords
- preparation
- weight reducing
- pharmaceutically acceptable
- astaxanthin
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 19
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 49
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 46
- 239000001168 astaxanthin Substances 0.000 claims abstract description 46
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 46
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 46
- 150000003839 salts Chemical class 0.000 claims abstract description 14
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 6
- DOJXGHGHTWFZHK-UHFFFAOYSA-N Hexachloroacetone Chemical compound ClC(Cl)(Cl)C(=O)C(Cl)(Cl)Cl DOJXGHGHTWFZHK-UHFFFAOYSA-N 0.000 claims description 50
- 239000000284 extract Substances 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 31
- 239000002775 capsule Substances 0.000 claims description 18
- 238000005303 weighing Methods 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims description 13
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims description 11
- 239000000905 isomalt Substances 0.000 claims description 11
- 235000010439 isomalt Nutrition 0.000 claims description 11
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 8
- 239000008101 lactose Substances 0.000 claims description 8
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 7
- 239000002994 raw material Substances 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- JXXCENBLGFBQJM-UHFFFAOYSA-N (3-carboxy-2-hydroxypropyl)-trimethylazanium;chloride Chemical compound [Cl-].C[N+](C)(C)CC(O)CC(O)=O JXXCENBLGFBQJM-UHFFFAOYSA-N 0.000 claims description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
- 229940089491 hydroxycitric acid Drugs 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- 150000001514 astaxanthins Chemical class 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 235000012424 soybean oil Nutrition 0.000 claims description 2
- 239000003549 soybean oil Substances 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 abstract description 4
- 230000003647 oxidation Effects 0.000 abstract description 4
- 238000007254 oxidation reaction Methods 0.000 abstract description 4
- 238000000354 decomposition reaction Methods 0.000 abstract description 3
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000013641 positive control Substances 0.000 description 25
- 238000002474 experimental method Methods 0.000 description 20
- 210000000577 adipose tissue Anatomy 0.000 description 13
- 238000012360 testing method Methods 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000036541 health Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 235000005911 diet Nutrition 0.000 description 7
- 230000037213 diet Effects 0.000 description 7
- 238000012856 packing Methods 0.000 description 7
- 239000011122 softwood Substances 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 208000008589 Obesity Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 206010013786 Dry skin Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 235000020985 whole grains Nutrition 0.000 description 3
- 102000004146 ATP citrate synthases Human genes 0.000 description 2
- 108090000662 ATP citrate synthases Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000002666 Carnitine O-palmitoyltransferase Human genes 0.000 description 2
- 108010018424 Carnitine O-palmitoyltransferase Proteins 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 238000005498 polishing Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241001132374 Asta Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000287127 Passeridae Species 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000010852 mitochondrial transfer Methods 0.000 description 1
- 230000026326 mitochondrial transport Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- -1 pulvis Substances 0.000 description 1
- 235000020989 red meat Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides a weight losing composition. The weight losing composition consists of L-carnitine or pharmaceutically acceptable salt thereof, astaxanthin and garcinia cambogia extract. The invention also provides a preparation containing the weight losing composition and a preparation method thereof. The composition for losing weight can accelerate the consumption of fat in the body, and can effectively convert in vivo fat into energy by oxidation and decomposition so as to fulfill the purposes of naturally controlling and reducing the weight.
Description
Technical field
The present invention relates to a kind of diet food, be specifically related to a kind of Weight reducing compound and preparation and preparation method who forms by l-cn, astaxanthin and HCA extract.
Background technology
Along with the raising gradually of people's living standard, food type and food supply be very abundant all.The diet that be in easy circumstances, allegro life causes is irregular, lacks motion etc., makes the absorption of body self-energy greater than consumption, fat accumulation, and adipocyte increases, and the fat of health surpasses normal level, thereby causes obesity.Obesity is a kind of metabolic chronic disease, can cause multiple disease by obesity, as hypertension, and high fat of blood, diabetes, coronary heart disease or the like.These illnesss health of engulfing the people just gradually all brought great influence for work and life, and the fat number of China is increasing with surprising rapidity, and problem of obesity can not be ignored.
At present, all kinds of diet food on the market are multifarious, food, medicine, health products or the like.Most of products or be to take appetite-suppressing, or be that the method for taking to suffer from diarrhoea or the like reaches the purpose of fat-reducing.Though some produces effect, also exist very big side effect, be a kind of infringement to the health of health.
L-cn (L-carnitine) claims L-carnitine, DL-carnitine chloride again, and chemical name is beta-hydroxy γ-trimethylamine butyric acid, is a kind of white crystalline lens or white transparent fine powder.L-cn is the moisture absorption very easily, and stable good can place in the solution of pH 3～6 more than 1 year, ability more than 200 ℃ high temperature and have molten preferably water-based and water imbibition.L-cn has been applied to fields such as medicine, health care and food at present.
Carnitine is that a kind of fat that promotes is converted into the amino acid of energy, and red meat is the main source of l-cn, and human body is had no side effect.Dissimilar diets has contained the l-cn of 5-100 milligram, but common people can only take in 50 milligrams every day from meals, and the vegetarian takes in still less.The major physiological function of l-cn is to promote that fat changes into energy, taking l-cn can be when reducing body fat, reducing body weight, do not reduce moisture and muscle, regarded as the safest fat-reducing nutrient complementary goods that has no side effect by international fat health tissues in 2003.
(Astaxanthin is a kind of blue or green plain ASTA) to astaxanthin, its chemical constitution is similar to beta carotene, and Chinese patent 200580047256.7 discloses the purposes that astaxanthin is used to reduce body fat.The people's such as Aoi of Tokyo provincial university in 2003 the astaxanthin that studies confirm that can the not oxidized destruction of better protect l-cn palmitoyl transferase, thereby promote aliphatic acid to mitochondrial transfer, strengthens lipid-metabolism.
Active ingredient Hydroxy Citric acidfu (HCA, hydroxycitric acid) in the HCA extract promotes the burning of aliphatic acid by suppressing the synthetic of fat, reduces the absorption of food, reaches the effect of weight reducing fat-reducing.The action principle of HCA exactly when human glucose transfers fat to, suppresses the activity of one of them ATP-citrate lyase, and aliphatic acid can't be synthesized, and suppresses the carrying out of glycolysis.
Therefore, the invention provides a kind of Weight reducing compound,, can more effectively make the body fat oxidation Decomposition be converted into energy, thereby reach the purpose of nature control and attenuating body weight by quickening the burning of fat in the health.
Summary of the invention
The purpose of this invention is to provide a kind of burning that can quicken fat in the health, can effectively make the body fat oxidation Decomposition be converted into energy, thereby reach the Weight reducing compound of the purpose of nature control and attenuating body weight.
Another object of the present invention is to provide the preparation of this Weight reducing compound.
In addition, the present invention also provides the preparation technology of the preparation of this Weight reducing compound.
A kind of Weight reducing compound provided by the invention is characterized in that, is made up of l-cn or its pharmaceutically acceptable salt, astaxanthin and HCA extract.
A kind of composition that is used to lose weight provided by the invention is made up of the raw material of following weight portion: 200～1000 parts of 500～5000 parts of l-cn or its pharmaceutically acceptable salts, 20～80 parts of astaxanthins and HCA extracts.
A kind of composition that is used to lose weight provided by the invention, further preferred, form by the raw material of following weight portion: 400～600 parts of 1000～2000 parts of l-cn or its pharmaceutically acceptable salts, 20～40 parts of astaxanthins and HCA extracts.
The unit of weight portion of the present invention can be the known unit of weights of field of medicaments such as μ g, mg, g, kg.
Described l-cn pharmaceutically acceptable salt is selected from one or more in L-carnitine-L-tartrate, l-cn fumarate or the L-carnitine hydrochloride.
Astaxanthin can directly be bought from the market.
Described HCA extract is the water extract of HCA, contains 60% hydroxycitric acid, can directly buy from the market.
The present invention also provides the preparation of this Weight reducing compound, is made up of Weight reducing compound and pharmaceutically acceptable carrier or diluent.
The present invention also provides the preparation of this Weight reducing compound, is made up of Weight reducing compound and the pharmaceutically acceptable carrier of 100-3000 weight portion or diluent.
The preparation of a kind of Weight reducing compound provided by the invention can be solid pharmaceutical preparation and liquid preparation, solid pharmaceutical preparation such as tablet, capsule, soft capsule, pulvis, liquid preparation such as oral liquid.
Described carrier of pharmaceutically accepting or diluent are selected from one or more in xylitol, D-sorbite, isomalt, isomaltoketose, sweet mellow wine, ethanol, microcrystalline cellulose, lactose, HPMC, soybean oil, the dolomol.
The present invention also provides a kind of preparation method who is used for the preparation of Weight reducing compound: get l-cn or its pharmaceutically acceptable salt, astaxanthin raw material and HCA extract, sieve, add pharmaceutically acceptable carrier or diluent, be prepared into regular dosage form.
The preparation of the various formulations of the present invention can adopt conventional method in the art to prepare, and also can prepare by the following method:
1) take by weighing l-cn or its pharmaceutically acceptable salt, astaxanthin, HCA extract, crushing screening, standby;
2) take by weighing pharmaceutically acceptable carrier or diluent, above-mentioned supplementary material is mixed according to the equivalent method of progressively increasing, be prepared into various regular dosage forms according to conventional formulation technology.
The present invention also provides a kind of using method of Weight reducing compound, and every day, oral or Instant Drinks were 1-3 time, each 3-5 grain or sheet or bag, every, bag or sheet count 0.1-1.0g to contain l-cn, astaxanthin-containing 0.001-0.5g contains HCA extract 0.01-0.5g.
Preparation compositions of the present invention has following beneficial effect:
The composition that is used to lose weight of the present invention, prescription carries out l-cn or its pharmaceutically acceptable salt, astaxanthin, HCA extract composite by special ratios, wherein, l-cn is the fatty acid oxidation carrier, fat can be transferred to mitochondria, in mitochondria, carry out oxidizing fire; Astaxanthin can improve and protect carnitine palmitoyltransferase (CPT1) activity, improves aliphatic acid to mitochondrial transport efficacy, impels fat as main fuel, thereby has strengthened fat metabolism; The HCA extract can suppress the activity of ATP-citrate lyase, reduces carbohydrate and is converted into fat.Three medicine proportionings, fat-reducing effect is more excellent, has the synergy of fat-reducing.
The specific embodiment
Following examples are used to illustrate the present invention, but are not used for limiting the scope of the invention.
Buying producer for l-cn, astaxanthin and HCA extract is in order to further specify realizability of the present invention, still should not to be used for limiting the scope of the invention.
Raw material l-cn of the present invention available from Shenyang Keshuo Nutrition Technology Co., Ltd., astaxanthin available from the biological Co., Ltd of Shanghai Lay sparrow, the HCA extract is available from system garden, Shanghai food technology Co., Ltd, wherein the HCA extract utilizes water to extract, and contains 60% hydroxycitric acid.
Embodiment 1: capsule:
1, prescription (weight): L-carnitine-L-tartrate 500g, astaxanthin 20g, HCA extract 200g, microcrystalline cellulose 100g, dolomol 5g.
2, preparation method:
1) take by weighing L-carnitine-L-tartrate, astaxanthin, HCA extract according to prescription, cross 40 mesh sieves respectively, standby;
2) take by weighing microcrystalline cellulose and dolomol according to prescription, above-mentioned supplementary material is mixed by the equivalent method of progressively increasing, pour capsule into and fill in the mould, can capsule, polishing, packing.
3, specification: contain l-cn 0.2g, astaxanthin 0.008g, HCA extract 0.08g in every capsules.
Embodiment 2: pulvis
1, prescription (weight): l-cn fumarate 5000g, astaxanthin 80g, HCA extract 1000g, isomalt 5000g.
2, preparation method:
1) take by weighing l-cn, astaxanthin, HCA extract according to prescription, cross 40 mesh sieves respectively, standby;
2) take by weighing isomalt according to prescription, above-mentioned supplementary material is mixed packing by the equivalent method of progressively increasing.
3, specification: every bag contains l-cn 0.2g, astaxanthin 0.0032g, HCA extract 0.04g.
Embodiment 3: tablet
1, prescription (weight): l-cn 2000g, astaxanthin 20g, HCA extract 400g, isomalt 1000g, lactose 1500g, dolomol 40.
2, preparation method
1) take by weighing l-cn, astaxanthin, HCA extract according to prescription, cross 40 mesh sieves respectively, standby;
2) take by weighing isomalt, lactose according to prescription, above-mentioned supplementary material is mixed by the equivalent method of progressively increasing, use 50% ethanol as adhesive, the system softwood, above-mentioned softwood is made particle through waving of 14 eye mesh screens in the granulator, particle is inserted in the multi-functional boiling drier, about 40 minutes of 50 ℃ of fluidized dryings, the control pellet moisture is 5%, whole grain adds dolomol then in particle, total mixing, compressing tablet, packing;
3, specification: every contains l-cn 0.2g, and astaxanthin-containing 0.002g contains HCA extract 0.04.
Embodiment 4: capsule
Substantially with embodiment 1, the prescription of different is this capsule is:
L-carnitine hydrochloride 1000g, astaxanthin 40g, HCA extract 500g, microcrystalline cellulose 100g, dolomol 10g make 5000.
Specification: every capsules contains l-cn 0.2g, astaxanthin 0.008g, HCA extract 0.1g.
Embodiment 5: pulvis
Substantially with embodiment 2, the component of different is this pulvis is:
L-cn 2000g, astaxanthin 20g, HCA extract 400g, isomalt 5000g.
Specification: every bag contains l-cn 0.2g, astaxanthin 0.002g, HCA extract 0.04g.
Embodiment 6: tablet
1, prescription (weight): l-cn 1000g, astaxanthin 20g, HCA extract 600g, isomalt 1000g, lactose 1500g, dolomol 40g.
2, preparation method
1) take by weighing supplementary material l-cn, astaxanthin, HCA extract, cross 40 mesh sieves respectively, standby;
2) take by weighing the pure and mild lactose of isomaltoketose according to prescription, above-mentioned supplementary material is mixed by the equivalent method of progressively increasing, use 50% ethanol as adhesive; the system softwood is made particle with above-mentioned softwood through waving of 14 eye mesh screens in the granulator, particle is inserted in the multi-functional boiling drier; about 40 minutes of 50 ℃ of fluidized dryings; the control pellet moisture is 5%, and whole grain adds dolomol then in particle; total mixing; compressing tablet, packing, promptly.
3, specification: every contains l-cn 0.2g, astaxanthin 0.004g, HCA extract 0.12g.
Embodiment 7: capsule:
1, prescription (weight): l-cn 2000g, astaxanthin 20g, HCA extract 600g, microcrystalline cellulose 100g, dolomol 5g.
2, preparation method:
1) take by weighing l-cn, astaxanthin, HCA extract according to prescription, cross 40 mesh sieves respectively, standby;
2) take by weighing microcrystalline cellulose and dolomol according to prescription, above-mentioned supplementary material is mixed according to the equivalent method of progressively increasing, pour capsule into and fill in the mould, the can capsule, polishing, packing contains promptly in every capsule.
3, specification: every capsules contains l-cn 0.2g, astaxanthin 0.002g, HCA extract 0.06g.
Embodiment 8: pulvis
1, prescription (weight): L-carnitine-L-tartrate 2000g, astaxanthin 40g, HCA extract 400g, isomalt 5000g.
2, preparation method:
1) take by weighing L-carnitine-L-tartrate, astaxanthin, HCA extract according to prescription, cross 40 mesh sieves respectively, standby;
2) take by weighing isomalt according to prescription, above-mentioned supplementary material is mixed by the equivalent method of progressively increasing, packing, promptly.
3, specification: every bag contains l-cn 0.2g, astaxanthin 0.004g, HCA extract 0.04g.
Embodiment 9: tablet
1, prescription (weight): l-cn 2000g, astaxanthin 40g, HCA extract 600g, isomalt 1000g, lactose 1500g, dolomol 40g.
2, preparation method
1) take by weighing l-cn fumarate, astaxanthin, HCA extract, cross 40 mesh sieves respectively, standby;
2) take by weighing the pure and mild lactose of isomaltoketose according to prescription, above-mentioned supplementary material is mixed by the equivalent method of progressively increasing, use 50% ethanol as adhesive; the system softwood is made particle with above-mentioned softwood through waving of 14 eye mesh screens in the granulator, particle is inserted in the multi-functional boiling drier; about 40 minutes of 50 ℃ of fluidized dryings; the control pellet moisture is 5%, and whole grain adds dolomol then in particle; total mixing; compressing tablet, packing, promptly.
3, specification: every contains l-cn 0.2g, astaxanthin 0.004g, HCA extract 0.06g.
Experimental example: human experimentation
1 experimental subjects and method
1.1 experimental subjects
This is tested whole experimenters and carries out constitutional index assessment respectively be obese people, male 28 examples among the 60 routine experimenters, women 32 examples before experiment; Age is between 22-40 year, year mean age (32.4 ± 6.5);
1.2 experiment grouping
Grouping: 80 experimenters are divided into eight groups at random, negative control group (N=10), positive controls A (N=10), positive controls B (N=10), positive controls C (N=10), experimental group A (N=10), experimental group B (N=10), experimental group C (N=10), experimental group D (N=10).Negative control group is taken placebo, 5/day; Positive controls A takes the l-cn capsule, 6/day (every contains the 0.6g l-cn); Positive controls B takes the astaxanthin capsule, 6/day (every astaxanthin-containing 0.024g); Positive controls C takes the HCA extract, 6/day (every contains HCA extract 0.24g); Experimental group A takes 6/day of Weight reducing compound capsule groups of the present invention (embodiment 1), experimental group B takes Weight reducing compound tablet group of the present invention (embodiment 3), 6/day, experimental group C takes Weight reducing compound capsule group of the present invention (embodiment 4), 6/day, experimental group D takes Weight reducing compound tablet group of the present invention (embodiment 6), 6/day, all takes continuously for 8 weeks.Whole experimental session is not kept on a diet, and does not painstakingly increase motion, and prohibits other diet food of clothes and medicine.
1.1.3 test index
1.1.3.1 body composition test: adopt the body weight of DX200 super strong type body composition test instrument test subject, body fat percentage, body-mass index before the experiment and after the experiment weekly.
1.1.4 data statistics
The gained data are handled with Excel, adopt single blind method and t check that test data is carried out statistical analysis, represent with mean ± SD.
2 experimental results and analysis
2.1 body composition analysis result
2.1.1 subject re-detection result before and after the experiment
Table 1: experimenter's body weight situation of change before and after the experiment
| Group | The example number | Before the experiment (kg) | Experiment back (kg) |
| Negative control group | 10 | 67.15±18.52 | 67.04±18.76 |
| Positive controls A | 10 | 64.71±15.58 | 62.57±16.56 * |
| Positive controls B | 10 | 66.71±14.34 | 64.07±12.67 * |
| Positive controls C | 10 | 65.57±15.36 | 62.93±16.58 * |
| Experimental group A | 10 | 66.15±17.58 | 62.93±17.35 **#&￥ |
| Experimental group B | 10 | 67.20±16.51 | 62.87±16.39 **#&￥ |
| Experimental group C | 10 | 66.45±15.57 | 61.79±14.76 **#&￥ |
| Experimental group D | 10 | 67.02±16.22 | 61.03±15.61 **#&￥ |
With take before compare, * P＜0.05, * * P＜0.01 and positive control A group is compared,
#P＜0.05; Compare with positive controls B group,
﹠amp;P＜0.05 is compared with positive control C group,
$P＜0.05
As can be seen from Table 1, after the experiment, comparing body weight before positive controls and experimental group and the experiment all has in various degree reduction, wherein positive controls A, B, C experiment back body weight significantly descend (P＜0.05); Compare after experimental group A, B, C, the D experiment and before testing, body weight extremely significantly reduces (P＜0.01).
Compare with positive control A, B, C group respectively, the body weight decline of experimental group A, B, C, D group is (P＜0.05) obviously.
2.1.2 body fat percentage testing result before and after the experiment
Table 2: experimenter's body fat percentage testing result
| Group | The example number | Before the experiment (%) | Experiment back (%) |
| Negative control group | 12 | 32.25±5.21 | 32.41±5.54 |
| Positive controls A | 12 | 31.65±6.02 | 29.14±6.42* |
| Positive controls B | 12 | 32.75±7.78 | 31.65±7.22* |
| Positive controls C | 12 | 32.58±6.79 | 29.95±7.03* |
| Experimental group A | 12 | 32.26±6.51 | 26.88±6.76 **#&￥ |
| Experimental group B | 12 | 31.95±6.05 | 26.85±7.18 **#&￥ |
| Experimental group C | 12 | 32.13±6.31 | 26.68±6.26 **#&￥ |
| Experimental group D | 12 | 32.25±5.85 | 26.13±7.03 **#&￥ |
With take before compare, * P＜0.05, * * P＜0.01 and positive control A group is compared,
#P＜0.05; Compare with positive controls B group,
﹠amp;P＜0.05 is compared with positive control C group,
$P＜0.05
As can be seen from Table 2, after the experiment, compare body fat before positive controls and experimental group and the experiment in various degree reduction is all arranged, positive controls A, B, C experiment back body fat significantly descend (P＜0.05) wherein, compare after experimental group A, B, C, the D experiment and before testing, body fat extremely significantly reduces (P＜0.01).
Compare with positive control A, B, C group respectively, the body fat decline of experimental group A, B, C, D group is (P＜0.05) obviously.
3 conclusions
Weight reducing compound of the present invention can be under the situation of not keeping on a diet and painstakingly not moving, can quicken the utilization of fat, in this experiment, compare with each control group, the amplitude of losing weight of experimental group is greater than positive controls and negative control group, and body fat percentage is conspicuousness and descends, and illustrates that the experimenter takes Weight reducing compound of the present invention fat reducing fat in weight reduction, body fat percentage descends, and then reaches the purpose of fat-reducing.Simultaneously, compare with taking l-cn or its pharmaceutically acceptable salt, astaxanthin and HCA extract separately, fat-reducing effect of the present invention is good, has synergy.
Though, above used general explanation, the specific embodiment and test, the present invention is described in detail, on basis of the present invention, can make some modifications or improvements it, and this will be apparent to those skilled in the art.Therefore, these modifications or improvements all belong to the scope of protection of present invention without departing from theon the basis of the spirit of the present invention.
Claims (10)
1. a Weight reducing compound is made up of l-cn or its pharmaceutically acceptable salt, astaxanthin and HCA extract.
2. Weight reducing compound according to claim 1 is characterized in that, said composition is made up of the raw material of following weight portion: 500～5000 parts of l-cn or its pharmaceutically acceptable salts, 20～80 parts of astaxanthins, 200～1000 parts of HCA extracts.
3. Weight reducing compound according to claim 2 is characterized in that, said composition is made up of the raw material of following weight portion: 400～600 parts of l-cn or its pharmaceutically acceptable salt 1000-2000 part, astaxanthin 20-40 part and HCA extracts.
4. according to claim 1,2 or 3 described Weight reducing compounds, it is characterized in that described pharmaceutically acceptable l-cn salt is selected from one or more in L-carnitine-L-tartrate, l-cn fumarate or the L-carnitine hydrochloride.
5. according to claim 1,2 or 3 described Weight reducing compounds, it is characterized in that described HCA extract is a water extract, contains 60% hydroxycitric acid.
6. according to the preparation of claim 1,2 or 3 described Weight reducing compounds, form by Weight reducing compound and pharmaceutically acceptable carrier or diluent.
7. the preparation of Weight reducing compound according to claim 6 is characterized in that, described preparation is selected from solid pharmaceutical preparation or liquid preparation.
8. the preparation of Weight reducing compound according to claim 7, described solid pharmaceutical preparation is selected from tablet, capsule, pulvis or soft capsule; Described liquid preparation is an oral liquid.
9. the preparation of Weight reducing compound according to claim 6, it is characterized in that described pharmaceutically acceptable carrier or diluent are selected from one or more in xylitol, D-sorbite, isomalt, isomaltoketose, sweet mellow wine, ethanol, microcrystalline cellulose, lactose, HPMC, soybean oil or the dolomol.
10. method for preparing the preparation of the described Weight reducing compound of claim 6, it is characterized in that, take by weighing l-cn or its pharmaceutically acceptable salt, astaxanthin, HCA extract raw material, sieve, add pharmaceutically acceptable carrier or diluent, mix, be prepared into conventional formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106080995A CN102150838A (en) | 2010-12-16 | 2010-12-16 | Weight losing composition, preparation containing same and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010106080995A CN102150838A (en) | 2010-12-16 | 2010-12-16 | Weight losing composition, preparation containing same and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102150838A true CN102150838A (en) | 2011-08-17 |
Family
ID=44432767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010106080995A Pending CN102150838A (en) | 2010-12-16 | 2010-12-16 | Weight losing composition, preparation containing same and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102150838A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103891962A (en) * | 2014-04-16 | 2014-07-02 | 江苏安康生物科技发展有限公司 | Health tea capable of beautifying face and losing weight and preparation method of health tea |
| CN106418526A (en) * | 2016-12-20 | 2017-02-22 | 乌鲁木齐上善元生物科技有限公司 | Conjugated linoleic acid type multifunctional food capable of reducing blood lipid and reducing weight |
| CN106605744A (en) * | 2016-08-25 | 2017-05-03 | 西安源森生物科技有限公司 | Composition capable of reducing fat, slimming, expelling toxin and beautifying, as well as preparation method thereof |
| CN109275823A (en) * | 2018-10-16 | 2019-01-29 | 山东柳竖脂商贸有限公司 | A kind of weight losing meal-replacing solid beverage and preparation method thereof |
| CN114424825A (en) * | 2022-04-02 | 2022-05-03 | 中科宜康（北京）生物科技有限公司 | Quintuple fat-reducing composition and preparation method and application thereof |
| CN115154574A (en) * | 2022-07-01 | 2022-10-11 | 王虹 | Herbal Qingvoxel |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101111239A (en) * | 2004-12-03 | 2008-01-23 | 富士化学工业株式会社 | Composition for body fat reduction |
| CN101132697A (en) * | 2004-04-30 | 2008-02-27 | 新Hc配方设计公司 | Weight loss composition and method of inducing weight loss |
| CN101224202A (en) * | 2007-12-26 | 2008-07-23 | 广州康采恩医药有限公司 | Weight reducing compound |
-
2010
- 2010-12-16 CN CN2010106080995A patent/CN102150838A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101132697A (en) * | 2004-04-30 | 2008-02-27 | 新Hc配方设计公司 | Weight loss composition and method of inducing weight loss |
| CN101111239A (en) * | 2004-12-03 | 2008-01-23 | 富士化学工业株式会社 | Composition for body fat reduction |
| CN101224202A (en) * | 2007-12-26 | 2008-07-23 | 广州康采恩医药有限公司 | Weight reducing compound |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103891962A (en) * | 2014-04-16 | 2014-07-02 | 江苏安康生物科技发展有限公司 | Health tea capable of beautifying face and losing weight and preparation method of health tea |
| CN103891962B (en) * | 2014-04-16 | 2016-03-30 | 江苏安康生物科技发展有限公司 | Health protection tea of a kind of beauty treatment weight reducing and preparation method thereof |
| CN106605744A (en) * | 2016-08-25 | 2017-05-03 | 西安源森生物科技有限公司 | Composition capable of reducing fat, slimming, expelling toxin and beautifying, as well as preparation method thereof |
| CN106418526A (en) * | 2016-12-20 | 2017-02-22 | 乌鲁木齐上善元生物科技有限公司 | Conjugated linoleic acid type multifunctional food capable of reducing blood lipid and reducing weight |
| CN109275823A (en) * | 2018-10-16 | 2019-01-29 | 山东柳竖脂商贸有限公司 | A kind of weight losing meal-replacing solid beverage and preparation method thereof |
| CN114424825A (en) * | 2022-04-02 | 2022-05-03 | 中科宜康（北京）生物科技有限公司 | Quintuple fat-reducing composition and preparation method and application thereof |
| CN115154574A (en) * | 2022-07-01 | 2022-10-11 | 王虹 | Herbal Qingvoxel |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103238897B (en) | Composite plant solid drink suitable for diabetic patients | |
| CN102150861B (en) | Nutritional supplement with functions of oxidation resistance and fatigue resistance | |
| CN102018832B (en) | Weight-reducing composition and preparation method thereof | |
| CN106360310A (en) | Composition for dropping after meal blood sugar and application thereof | |
| CN102150838A (en) | Weight losing composition, preparation containing same and preparation method thereof | |
| CN102048884B (en) | Weight-losing composition containing guarana extract | |
| CN104489681A (en) | Composition with function of enhancing immunity, health product and preparation method thereof | |
| CN104432063B (en) | Composition for alleviating athletic fatigue and preparation method thereof | |
| RU2665635C2 (en) | Multivitamin/mineral composition for controlling environmental stress effects; improving immunity and increasing activity, aiming at vitamin and mineral insufficiency with no negative side effects of mega-dosage food additive | |
| CN101185706B (en) | Hippophae rhamnoides nutrition mixture with delaying senility function and preparation technique thereof | |
| CN101224202A (en) | Weight reducing compound | |
| CN102847159A (en) | A glucose metabolism enhancer | |
| CN104856000A (en) | Insomnia non-complete nutritional formula food | |
| CN104000181A (en) | Composition for relieving physical fatigue and preparation method thereof | |
| CN103621871B (en) | Compound amino acid health-care product and preparation method thereof | |
| CN110326776A (en) | A kind of integration of drinking and medicinal herbs compound formulation of the raising immunity of suitable spacefarer | |
| CN109528905A (en) | A kind of health food of warming and invigorating kidney Yang and preparation method thereof | |
| RU2817886C1 (en) | Dry beverage concentrate for bone tissue recovery | |
| JP2005126379A (en) | New synergetic composition of vitamins, minerals and trace element for stimulating elimination of intracellular lipid deposit | |
| CN102266051A (en) | Antifatigue composition and preparation method thereof | |
| US20130224298A1 (en) | Two-Phase Preparation And Use Thereof For The Treatment Of Herpes | |
| CN109998102B (en) | L-carnitine lotus leaf green tea capsule and preparation method thereof | |
| CN101731624A (en) | Compound male silkworm moth health-care food for resisting senility and regulating immunity and preparation method | |
| CN107496852A (en) | A kind of composition with effect of weight reducing and preparation method thereof, purposes | |
| CN1853654B (en) | Oral preparation containing pearl and vitamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20110817 |